Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Mai… (NCT07583550) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer
43 participantsStarted 2026-05-01
Plain-language summary
This multicenter, prospective study aims to investigate the efficacy and safety of low-dose radiotherapy (15Gy/1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy plus anti-PD-L1 antibody, followed by anti-PD-L1 antibody maintenance for up to two years, in participants with extensive-stage small cell lung cancer (ES-SCLC).
Additionally, dynamic monitoring using next-generation sequencing (NGS) technology will be performed to assess ctDNA levels, genetic information, and mutation abundance at the following time points: before and after low-dose radiotherapy, after 4-6 cycles of chemotherapy plus anti-PD-L1 antibody (chemotherapy-immunotherapy), and before the initiation of anti-PD-L1 maintenance therapy. This approach aims to guide efficacy and prognosis prediction, as well as to identify potential biomarkers associated with treatment response.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Age ≥18 years and ≤75 years.
. Histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC).
. No prior systemic anti-tumor therapy.
. ECOG performance status 0-2 and life expectancy ≥12 weeks.
. At least one measurable lesion per RECIST version 1.1.
. No brainstem metastasis and no significant neurological symptoms from brain metastases.
. All participants must undergo routine contrast-enhanced CT of the chest and upper abdomen, as well as brain MRI, before enrollment. Whole-body PET-CT plus brain MRI is preferred. For participants with limited financial resources who also have significant obstructive pneumonia or atelectasis, an additional chest MRI is recommended.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Progression-Free Survival（PFS）
Timeframe: From the date of first radiotherapy to the date of first documented disease progression, metastasis, or death from any cause, assessed up to 24 months.
. No malignant pleural effusion or pericardial effusion.
Exclusion criteria
. Presence of interstitial pneumonia or infectious fever prior to treatment.
. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment).
. Prior history of thoracic radiotherapy or thoracic surgery.
. Presence of Grade ≥3 hematologic toxicity or hepatic/renal impairment.
. Hypersensitivity to adebrelimab.
. Significant respiratory symptoms that preclude tolerance to radiotherapy.
. Active hepatitis B or hepatitis C infection with ongoing antiviral therapy. Subjects with a documented history of HBV infection who have achieved undetectable HBV levels after prior active treatment at the time of enrollment may be included.
. Presence of pleural effusion or pericardial effusion.